Retatrutide is Eli Lilly's GLP-1/GIP/glucagon triple agonist, now the most efficacious obesity peptide ever read out in Phase 3. Phase 2 work showed mean weight loss above 24% at 48 weeks plus an 86% reduction in liver fat at 48 weeks, ahead of every approved drug.
TRIUMPH-1 topline released May 21, 2026 is the registrational readout that anchors the planned BLA. In 2,339 adults with obesity or overweight and at least one weight-related comorbidity without diabetes, retatrutide produced 28.3% mean weight loss at 12 mg, 25.9% at 9 mg, and 19.0% at 4 mg over 80 weeks versus 2.2% on placebo. 45.3% of participants on 12 mg reached ≥30% weight loss — bariatric-surgery territory. A 104-week extension in the BMI ≥35 subgroup pushed mean weight loss to 30.3% (85.0 lbs). Transient ALT elevations that surfaced in TRIUMPH-4 reappeared and normalized by week 24, consistent with hepatic triglyceride mobilization. Discontinuation rates ran 4.1%, 6.9%, and 11.3% across 4, 9, and 12 mg arms versus 4.9% placebo. TRIUMPH-4 in obesity with knee osteoarthritis posted 28.7% mean weight loss at 68 weeks plus 75.8% reduction in WOMAC pain. TRANSCEND T2D1 in type-2 diabetes reported A1c down 1.7 to 2.0 percentage points and 25 to 37 lb mean weight loss versus placebo. On July 23, 2026, Lilly reported TRIUMPH-2 and TRIUMPH-3 topline results using the efficacy estimand. In TRIUMPH-2 (1,152 adults with type 2 diabetes and obesity or overweight), the 12 mg dose produced 20.8% weight loss and an A1C reduction of up to 1.6 percentage points at 80 weeks, versus 4.0% and 0.2 points on placebo. In TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease), 12 mg produced 22.6% weight loss versus 3.2% on placebo at 80 weeks. Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027 for obesity, knee osteoarthritis pain, and obstructive sleep apnea. The 10,000-patient TRIUMPH-OUTCOMES cardiovascular trial reads out 2027. Full TRIUMPH-1 data landed at ADA 2026 (June 5-8, New Orleans). Full TRIUMPH-2 results were published in The Lancet and presented at EASD on September 30, 2026, reporting dysesthesia in 4.5% to 7.3% of retatrutide patients versus 0.7% on placebo.
Retatrutide has also leaked into the unregulated research-peptide channel; the April 2026 Utah federal indictment of an osteopathic physician for selling 200+ patients misbranded Chinese peptides named retatrutide alongside semaglutide, tirzepatide, and BPC-157. The access fight took a sharper political turn on June 23, 2026 when STAT News disclosed that the FDA and Lilly granted a mystery 79-year-old patient compassionate-use access to retatrutide on the application of NIH senior clinician Dr. Ranganath Muniyappa, citing refractory obesity plus OSA plus pulmonary hypertension; outside experts told STAT the diagnoses don't clearly meet the compassionate-use threshold and the White House had to publicly deny that President Trump (who turned 80 on June 14) applied. The political escalation continued through June 24-25: White House senior deputy press secretary Kush Desai attacked STAT reporter Lizzy Lawrence as 'an unserious gossip columnist' (June 23-24), Rep. Ted Lieu (D-CA) suggested Trump canceled the 21st Century ROAD to Housing bill signing because he is receiving an experimental drug for terminal illness (June 24, prompting White House Communications Director Steven Cheung to call Lieu a 'dumba--'), and Senator Maggie Hassan (D-NH) sent a formal letter to HHS Secretary RFK Jr. on June 25 demanding answers and characterizing the use as 'a highly anticipated medication for obesity to a single VIP individual for free.' Lilly issued its first public statement on June 25: 'We make these decisions following all applicable regulations.' Stories here cover the trial readouts, mechanism work, the access-equity debate, the political fallout, and the gray-market enforcement track.
Coverage week of June 15-19 distilled the post-ADA market share story: Eli Lilly's tirzepatide franchise (Mounjaro for T2D, Zepbound for obesity) now holds 54.8% of US GLP-1 prescription share versus 47% a year earlier, with Q1 2026 YoY growth of 125% for Mounjaro and 80% for Zepbound and full-year revenue guidance raised to $82-85B. Novo Nordisk lifted its own 2026 guidance to a 4-12% currency-adjusted decline (improved from 5-13%) on Wegovy pill momentum (3M US scripts in five months, 65% of new prescriptions, 82% to GLP-1-naive patients), but Novo's stock has declined 42% over the past year against Lilly's 40% gain — the share-shift signal the ADA cycle crystallized. Lilly's seven additional retatrutide Phase 3 readouts across 2026 (TRIUMPH-7 chronic low-back pain, TRIUMPH-8 general obesity, TRIUMPH-9 obesity without T2D, plus OSA, MASLD, and cardiometabolic outcomes) extend the franchise gap.
Lexaria Bioscience (NASDAQ: LEXX) announced June 9, 2026 that dosing has been completed in Animal Study #2 (GLP-1-A26-2) evaluating its DehydraTECH oral peptide delivery platform with two next-generation GLP-1 drugs: Eli Lilly's retatrutide (triple GIP/GLP-1/glucagon agonist) and Novo Nordisk's amycretin (unimolecular GLP-1/amylin agonist). The study tested formulation enhancements designed to improve DehydraTECH performance and stake intellectual property claims on next-generation oral GLP-1 delivery. The data follows Lexaria's April 23 study launch and feeds the broader oral GLP-1 platform competition with Novo Nordisk's Wegovy pill (3M US prescriptions in 5 months) and Lilly's orforglipron (Foundayo, approved April 2026). Lexaria's industry update June 17 framed the oral GLP-1 pill segment as 'billions in new industry sales' potential.
The full TRIUMPH-1 safety dataset clarified the retatrutide dysesthesia signal: 20.9% of patients on 12 mg reported tingling, tenderness, or altered sensation, versus 8.8% at 9 mg and 0.7% on placebo. The signal is dose-dependent, generally mild to moderate, and Lilly says it is being monitored across all ongoing TRIUMPH trials. The data sit alongside the arrhythmia signal (7/403 retatrutide, 3 MACE versus 0 placebo) that STAT flagged on June 6 and now constitute the field's main retatrutide-specific safety conversation.
A Medscape ADA wrap on June 8 framed the post-GLP-1 era taking shape across the meeting: amylin analogs (petrelintide, cagrilintide, eloralintide) targeting GI-intolerance, triagonists (retatrutide), antibody-peptide conjugates (Amgen's maridebart cafraglutide/MariTide), and preclinical acceleration through AI peptide-design platforms. Each angle aims at the population gap that current GLP-1 monotherapy leaves: the patients who quit for tolerability, the ones who plateau, and the ones who need additional metabolic effects beyond appetite.
At Saturday's Phase 3 retatrutide symposium, Lilly presented the full TRIUMPH-1 dataset in 2,339 adults with obesity or overweight without diabetes. Mean weight loss reached 28.3% (70.3 lbs) at 12 mg over 80 weeks, with 45.3% of 12 mg patients reaching at least 30% loss; in a BMI ≥35 extension, the 12 mg arm hit 30.3% (85.0 lbs) at 104 weeks. Cardiometabolic side effects included up to 41.0% triglyceride drop, 24.2% non-HDL drop, 12.3 mmHg systolic blood pressure drop, and 24.1 cm waist reduction. The 4 mg dose still produced 19.0% weight loss with discontinuation below placebo.
The first Phase 3 retatrutide diabetes trial, TRANSCEND-T2D-1, was simultaneously published in The Lancet and presented at the June 6 symposium. In adults with type 2 diabetes inadequately controlled on lifestyle alone, retatrutide produced A1C reductions of up to 2.0 percentage points and weight loss of up to 16.8% (36.6 lbs) at 40 weeks, with up to 46% achieving a normal A1C — a threshold rare in diabetes treatment trials. Systolic blood pressure and lipid markers improved across doses.
STAT reported June 6 that new safety data presented at ADA showed seven of 403 retatrutide-treated patients experienced arrhythmias and three had major cardiovascular events, compared with none in the placebo group. The signal had been a watch item ahead of ADA because retatrutide adds glucagon-receptor activity to GLP-1 and GIP, raising heart-rate and energy-expenditure mechanisms that have not appeared in the same way for semaglutide or tirzepatide. Lilly's larger TRIUMPH-OUTCOMES cardiovascular trial reads out in 2027.
ADA 2026 brought full TRIUMPH-4 results in adults with obesity and knee osteoarthritis. At the 12 mg dose, mean weight loss reached 28.7% at 68 weeks, and WOMAC pain scores dropped by an average of 4.5 points, a 75.8% reduction. The combination of substantial weight loss with a directly measured pain-and-function benefit positions retatrutide as the first obesity drug to land both endpoints in a single Phase 3.
Beyond TRIUMPH-1 and TRANSCEND-T2D-1, Lilly confirmed at ADA that seven additional Phase 3 retatrutide readouts span obesity, type 2 diabetes, osteoarthritis, obstructive sleep apnea, chronic low-back pain, metabolic dysfunction-associated steatotic liver disease (MASLD), and the cardiometabolic-outcomes program. The MASLD readout is on track for H1 2027, and TRIUMPH-OUTCOMES (cardiovascular events in a 10,000-patient population) anchors the late-2027 timeline.
The 86th ADA Scientific Sessions opened June 5 in New Orleans with the late-breaker embargo lifting at 6:30 p.m. CT. Saturday's June 6 Phase 3 retatrutide symposium brings full TRIUMPH-1 (28.3% mean weight loss at 80 weeks) and TRANSCEND-T2D-1 data; Monday's June 8 orforglipron ACHIEVE symposium covers head-to-head data against oral semaglutide and dapagliflozin; Roche, Novo Nordisk, and Boehringer all run investor events the same day.
The American Diabetes Association's 86th Scientific Sessions run June 5-8, with a Phase 3 retatrutide symposium June 6 (TRIUMPH-1 and TRANSCEND-T2D-1) and a Foundayo/orforglipron symposium June 8. Beyond Lilly and Novo, the oral-incretin race fills the program: Structure's aleniglipron, Hengrui and Kailera's oral GLP-1/GIP ribupatide (up to 12.1% in Phase 2), and Boehringer/Zealand's survodutide SYNCHRONIZE-1 in obesity. More than 12,000 attendees are expected.
A study in the International Journal of Obesity compared semaglutide, tirzepatide, and retatrutide in MC4R-knockout mice, a model of the most common monogenic obesity. Over 21 days, mean body-weight reduction reached 31.6% with tirzepatide, 24.1% with retatrutide, and 19.7% with semaglutide, and tirzepatide also suppressed cumulative food intake most aggressively. All three improved plasma insulin, HOMA-IR, cholesterol, and liver-damage markers, suggesting incretin drugs can drive weight loss even when the POMC-MC4R satiety axis is disrupted.
The American Diabetes Association's 86th Scientific Sessions open June 5-8 with the year's deepest metabolic-peptide slate. Lilly presents full TRIUMPH-1 obesity data and the first retatrutide diabetes Phase 3, TRANSCEND-T2D-1, plus the orforglipron ACHIEVE program comparing the oral GLP-1 against dapagliflozin, oral semaglutide, and placebo. Innovent's mazdutide brings GLORY-2 and the DREAMS-3 head-to-head versus semaglutide, AstraZeneca's eleglipron carries full Phase 2b data, and Lilly's GLP-1/GIP/glucagon/amylin/calcitonin quintuple agonist takes a plenary slot.
Eli Lilly will present full data on retatrutide, Foundayo (orforglipron), and Mounjaro at the American Diabetes Association's 86th Scientific Sessions. The triple agonist retatrutide lowered A1C by up to 2.0% and drove 16.8% weight loss, about 36.6 lbs at the 12 mg dose, over 40 weeks in its first Phase 3 diabetes trial, TRANSCEND-T2D-1. Oral Foundayo beat oral semaglutide head-to-head with 73.6% greater relative weight loss and an A1C reduction of up to 1.7% against 0.8% for dapagliflozin.
The Sunday coverage cycle on Lilly's Thursday TRIUMPH-1 readout settled into broadly favorable consensus. Leerink's David Risinger characterized the data as 'raising the bar for future novel obesity drug developers'; RBC Capital's Trung Huynh framed it as a 'clean win for Lilly'; Dan Skovronsky (Lilly CSO) called 30% weight loss 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' Mainstream press coverage — NPR, BioPharma Dive, CNBC, Good Morning America — uniformly led with the bariatric-surgery-territory framing (45.3% of 12 mg participants reaching ≥30% weight loss). The dysesthesia signal (12.5% at 12 mg) registered in pharma-industry coverage and analyst commentary but received minimal mainstream-press attention. The TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + CVD) readouts later in 2026 are the next inflection points; the NDA filing follows in Q4 2026 or Q1 2027.
Day-after analyst commentary on Lilly's Thursday TRIUMPH-1 topline split favorably across major sell-side and management voices. Leerink Partners' David Risinger wrote that 'tolerability and substantial weight loss shown by retatrutide is raising the bar for future novel obesity drug developers,' a framing that lands at the higher end of the analyst spectrum after William Blair's tolerability-confined assessment Thursday. RBC Capital Markets' Trung Huynh characterized the readout as a 'clean win for [Lilly]' citing the clean safety profile plus best-in-class efficacy across all three doses. Dan Skovronsky, Lilly's chief scientific and product officer, told CNBC over the weekend that 30% weight loss in the BMI ≥35 extension is 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' The Saturday-Sunday news-cycle handling has settled into broadly favorable territory.
The TRIUMPH-1 dysesthesia signal (skin tingling, paresthesia-like sensations) that BMO Capital flagged Thursday merits a mechanistic look. The signal appeared in 12.5% of participants on retatrutide 12 mg in TRIUMPH-1, but was NOT reported in the Phase 2 retatrutide program. TRIUMPH-4 (December 2025 readout) recorded dysesthesia in approximately 20.9% of participants on the highest dose — most cases mild and resolving during ongoing treatment. The mechanistic explanation is tied to retatrutide's glucagon-receptor activation: glucagon signaling drives small-fiber sensory neuropathy patterns through downstream effects on c-AMP-mediated nociceptor sensitization. The pattern is dose-dependent (4 mg essentially no signal, 9 mg modest, 12 mg the peak). The clinical question is whether dysesthesia stays mild and reversible at commercial scale or whether a small fraction of patients develop persistent or more severe sensory disturbances. The signal is the differentiator from tirzepatide (no glucagon arm) and semaglutide (no glucagon, no GIP).
The European Association for the Study of the Liver (EASL) Congress 2026 runs May 27-30 in Barcelona. Novo Nordisk said it will present ESSENCE trial analyses of semaglutide in MASH, including a liver safety analysis led by Philip Newsome, an analysis in menopausal women led by Mazen Abdelmalek, and a Japanese subgroup analysis led by Atsushi Nakajima, building on the August 2025 FDA approval of semaglutide for MASH with fibrosis. Elsewhere in the field, Lilly's Phase 3 SYNERGY-Outcomes trial (NCT07165028) is enrolling about 4,500 people with MASLD to test tirzepatide and retatrutide against placebo on serious liver outcomes, and Boehringer Ingelheim's survodutide is in the Phase 3 LIVERAGE and LIVERAGE-Cirrhosis MASH trials.